Home / Business and Economy / Halozyme Therapeutics Beats Estimates with 69% Earnings Jump
Halozyme Therapeutics Beats Estimates with 69% Earnings Jump
6 Aug
Summary
- Halozyme's Q2 2025 adjusted earnings up 69.2% year-over-year
- Revenues surged 41% to $325.7 million, topping estimates
- Robust demand for subcutaneous drugs using Halozyme's Enhanze technology
Halozyme Therapeutics has reported impressive financial results for the second quarter of 2025. The company's adjusted earnings per share surged 69.2% year-over-year to $1.54, significantly exceeding the Zacks Consensus Estimate of $1.23.
Revenues also saw a substantial increase, rising 41% to $325.7 million and surpassing the consensus estimate of $286 million. This top-line growth was primarily driven by higher royalty payments from Roche for Phesgo and J&J for subcutaneous Darzalex, as well as argenx's Vyvgart Hytrulo.
Halozyme's Enhanze technology has been a key driver of the company's success, as several pharmaceutical firms use it to develop subcutaneous formulations of their marketed drugs. The company now has multiple partnered drugs based on this technology, including the subcutaneous versions of J&J's Darzalex and Roche's Phesgo.
Reflecting the strong performance, Halozyme has raised its full-year 2025 revenue guidance to a range of $1.28 billion to $1.36 billion, up from the previous projection of $1.20 billion to $1.28 billion.
